Inactive

Title: SARS-CoV-2 Nucleocapsid and Spike AlphaLISA assays (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with ... Title: SARS-CoV-2 Nucleocapsid and Spike AlphaLISA assays (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N9521Q00021 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions – NCATS Section, on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to PerkinElmer Health Sciences, Inc., 710 Bridgeport Ave., Shelton, CT 06484-4750, to purchase SARS-CoV-2 Nucleocapsid and Spike AlphaLISA assays. The anticipated award date is on or around December 9, 2020. This acquisition is non-competitive due to the need for consistency with previous use of these proprietary reagents in multiple screening assays in the NCATS laboratory. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2021-02 dated November 23, 2020. (iv) The associated NAICS code is 325413 and the small business size standard is 1250 employees. This acquisition is not set aside for small business. (v) This requirement consists of the following line items: Line 0001: Custom SARS-CoV2 Spike S1 AlphaLISA assay Includes QC and reproducibility 5 x 1,000 tests in 80uL final volume, 1 ea., catalog # CUSM05178000EA. Line 0002: Custom SARS-CoV2 Nucleocapsid AlphaLISA assay Includes QC and reproducibility 5 x 1,000 tests in 80uL final volume, 1 ea., catalog # CUSM05178000ZEA Line 0003: Shipping and handling, if applicable. (vi) Delivery shall be to: The National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850 Delivery shall be within 2 (two) to 3 (three) weeks after receipt of order, unless otherwise specified by the vendor. (vii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition. (viii) The award resulting from this solicitation will be made to the responsible offeror whose proposal is most advantageous to the Government, price and other factors considered. (ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Items, with offers. (x) The FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition. The following addendum applies: FAR 52.212-4 Addendum – Supplier License Agreements, attached. The following FAR provisions or clauses are incorporated by reference: 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Aug 2020) 52.204-18, Commercial and Entity Code Maintenance (Aug 2020) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015). 52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014), and the NIH electronic invoice instructions, attached. Offerors must complete and return the FAR representation 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020), attached. (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Items, applies to this acquisition. (xii) This synopsis is not a request for competitive proposals. All responsible sources may submit a bid, proposal or quotation which shall be considered by the agency. (xiii) In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by 11:00 a.m. Eastern time, December 4, 2020, and reference solicitation no. 75N9521Q00021. Responses must be submitted by email to Renato Gomes, Contract Specialist, renato.gomes@nih.gov, tel. (301) 451-2596. Attachments: 1 - FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) 2 - FAR 52.212-4 Addendum – Supplier License Agreements 3 - FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Items 4 - NIH Invoice and Payment Instructions